Find information and resources about the Research Institute's COVID-19 response
HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
This purpose of this study is to determine the efficacy and safety of tisagenlecleucel (also referred to as CTL019, or Kymriah™) in children, adolescents and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).
Using new understanding of the microbiome to design interventions to promote health and cure disease.